GlobeNewswire Inc.··Faruqi & Faruqi, LlpUltragenyx Stock Tumbles on Failed Drug Trials; Class Action Deadline Looms
Securities class action filed against $RARE over alleged misstatements about setrusumab drug efficacy. Failed clinical trials triggered 25-42% stock declines. Investor deadline: April 6, 2026.
RAREsecurities class actionmisleading statements